Verrica Pharmaceuticals Inc.
Verrica develops dermatological treatments including YCANTH® (cantharidin), FDA-approved for molluscum contagiosum in patients aged 2+, and VP-315 for non-melanoma skin cancers.
DEF 14AAug 24Latest SEC filing, period to Sep 17
Aug 6Latest story
August 2026